Box-dependent Myc-interacting protein (BIN1) compositions and uses therefor

Abstract

The present invention provides Bin1 genomic sequences and proteins encoded thereby. Also provided are compositions and methods utilizing these sequences and proteins in the diagnosis and treatment of cancers and hyperplastic disease states. Further provided are oligonucleotides derived from sequences encoding Bin1, as well as compositions and methods utilizing same for diagnostic and therapeutic purposes.

What is claimed is:  
     
         1 . An anti-Bin1 antibody specific for a Box-dependent myc-interacting peptide (Bin1) selected from the group consisting of 
 (a) the peptide encoded by Exon 12A; SEQ ID NO: 16;    (b) the peptide encoded by Exon 12B; SEQ ID NO: 18;    (c) the peptide encoded by Exon 12C; SEQ ID NO: 20:    (d) the peptide encoded by Exon 12D; SEQ ID NO: 22;    (e) fragments of (a) through (d) comprising at least about 8 amino acids, and    (e) analogues of (a) through (d) characterized by having at least 90% homology with SEQ ID NO 16, 18, 20 or 22    
     
     
         2  The antibody according to  claim 1 , selected from the group consisting of a chimeric antibody, a humanized antibody, a monoclonal antibody and a polyclonal antibody.  
     
     
         3  A diagnostic reagent comprising the antibody according to  claim 1  and a detectable label.  
     
     
         4 . A method of detecting a cancer or a hyperplastic disease state associated with a deficiency in normal Bin1 and/or abnormal levels of non-functional Bin1 comprising providing a biological sample from a patient suspected of having said cancer or disease and incubating said sample in the presence of a diagnostic reagent according to  claim 3 .  
     
     
         5 . A method of detecting prostate cancer comprising the steps of: 
 (a) providing a sample from a patient suspected of having prostate cancer;    (b) contacting said sample with an anti-Bin1 antibody according to  claim 1 , and    (c) detecting binding of said anti-Bin1 antibody to said sample.    
     
     
         6 . A therapeutic composition comprising a Bin 1 nucleic acid sequence of  claim 1  and a pharmaceutically acceptable carrier.  
     
     
         7 . The composition according to  claim 6 , wherein said composition comprises a vector comprising a Bin 1 nucleic acid sequence.  
     
     
         8 . A Bin 1 peptide having an amino acid sequence selected from the group consisting of 
 (a) the peptide encoded by Exon 12A SEQ ID NO: 16    (b) the peptide encoded by Exon 12B SEQ ID NO: 18,    (c) the peptide encoded by Exon 12C SEQ ID NO: 20,    (d) the peptide encoded by Exon 12D SEQ ID NO: 22,    (e) a fragment of any of (a) through (d) comprising at least 8 amino acids in length; and    (f) an analog of any of (a) through (e) having at least 90% homology with SEQ ID NO: 16, 18, 20 or 22.    
     
     
         9 . A therapeutic composition comprising a pharmaceutically acceptable carrier and a Bin 1 peptide of  claim 8 .  
     
     
         10  The method according to  claim 4 , wherein said cancer is a carcinoma or epithelial cell cancer  
     
     
         11 . The method according to  claim 4 , wherein said cancer is melanoma.  
     
     
         12 . The method according to  claim 10 , wherein said cancer is selected from the group consisting of prostate cancer, liver cancer and colorectal cancer.